CRVS - Corvus Pharmaceuticals, Inc.
IEX Last Trade
5.31
0.030 0.565%
Share volume: 36,933
Last Updated: Thu 26 Dec 2024 08:30:12 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$5.28
0.03
0.57%
Fundamental analysis
21%
Profitability
25%
Dept financing
4%
Liquidity
48%
Performance
15%
Performance
5 Days
7.69%
1 Month
-43.87%
3 Months
-3.73%
6 Months
173.74%
1 Year
184.88%
2 Year
530.47%
Key data
Stock price
$5.31
DAY RANGE
$4.92 - $5.37
52 WEEK RANGE
$1.44 - $10.00
52 WEEK CHANGE
$181.61
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Richard A. Miller
Region: US
Website: corvuspharma.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: corvuspharma.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Corvus Pharmaceuticals, Inc. focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company was incorporated in 2014 and is based in Burlingame, California.
Recent news